As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...